IN2014DN08939A - - Google Patents

Info

Publication number
IN2014DN08939A
IN2014DN08939A IN8939DEN2014A IN2014DN08939A IN 2014DN08939 A IN2014DN08939 A IN 2014DN08939A IN 8939DEN2014 A IN8939DEN2014 A IN 8939DEN2014A IN 2014DN08939 A IN2014DN08939 A IN 2014DN08939A
Authority
IN
India
Prior art keywords
low
therapeutic compounds
low solubility
formulations
basicity
Prior art date
Application number
Inventor
David E Pereira
Sara Wu
Prabhavathi Fernandes
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of IN2014DN08939A publication Critical patent/IN2014DN08939A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Pharmaceutical compositions adapted for the parenteral administration including intravenous administration of triazole containing macrolide antibiotics and methods or their use in the treatment of bacterial protozoal and other infections are described herein. Also described herein are solid solution and liquid formulations for such other therapeutic compounds that are characterized by low solubility and/or low basicity. It has been surprisingly discovered that the formulations described herein that include of one or more lactic acids one or more amino acids or combinations thereof including any pharmaceutically acceptable salts of the foregoing are useful for the parenteral delivery of such low solubility and/or low basicity therapeutic compounds.
IN8939DEN2014 2012-03-27 2013-03-27 IN2014DN08939A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616196P 2012-03-27 2012-03-27
US201361783026P 2013-03-14 2013-03-14
PCT/US2013/034179 WO2013148891A1 (en) 2012-03-27 2013-03-27 Parenteral formulations for administering macrolide antibiotics

Publications (1)

Publication Number Publication Date
IN2014DN08939A true IN2014DN08939A (en) 2015-05-22

Family

ID=49261221

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8939DEN2014 IN2014DN08939A (en) 2012-03-27 2013-03-27

Country Status (15)

Country Link
US (2) US10188674B2 (en)
EP (1) EP2830632A4 (en)
JP (2) JP6208742B2 (en)
KR (1) KR20140139083A (en)
CN (1) CN104470527B (en)
AU (1) AU2013239696C1 (en)
CA (1) CA2868262A1 (en)
HK (2) HK1205939A1 (en)
IL (2) IL234769A (en)
IN (1) IN2014DN08939A (en)
MX (1) MX2014011537A (en)
NZ (1) NZ700182A (en)
RU (1) RU2658050C2 (en)
SG (1) SG11201405895UA (en)
WO (1) WO2013148891A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552682T3 (en) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Novel antibacterial agents
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Process for the preparation of macrolide antibacterial agents
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc Hydrogen bond forming fluoro ketolides for treating diseases
KR20140139083A (en) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. Parenteral formulations for administering macrolide antibiotics
JP6426696B2 (en) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド Methods and formulations for the treatment of respiratory diseases
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN111825733A (en) 2013-04-04 2020-10-27 哈佛大学的校长及成员们 Macrolides and methods of making and using the same
CN106998685A (en) 2014-10-08 2017-08-01 哈佛大学的校长及成员们 14 yuan of ketone lactones and its preparation and application
CN107530365A (en) 2015-03-25 2018-01-02 哈佛大学的校长及成员们 Macrolide of desosamine sugar with modification and application thereof
WO2018152424A1 (en) * 2017-02-17 2018-08-23 Cempra Pharmaceuticals, Inc. Triazole-containing macrolides and ophthalmic uses therefor
CN109394200B (en) * 2018-12-16 2021-10-19 冯兴怀 Microcirculation pulse blood flow monitoring system and method for liquid treatment and volume management

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) * 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
GB891617A (en) 1959-09-02 1962-03-14 Clifford Brothers Ltd Lever handle for operating a latch or the spring bolt in a lock
US3843787A (en) * 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
US3843767A (en) 1972-03-27 1974-10-22 Du Pont Process for treating fluophosphate ores
SE458505B (en) * 1979-07-10 1989-04-10 Lepetit Spa APPLICATION OF RIFAMYCIN SV AND SALTS THEREOF PREPARING A PREPARATION FOR TREATMENT OF REUMATOID ARTHRITIS AND CERTAIN SALTS AND THEIR PREPARATION
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59104326A (en) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd Stable oral preparation of macrolide antibiotic substance, and method for stabilizing the same
JPS59175414A (en) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd Stable oral preparation of macrolide antibiotic substance and method for stabilizing the same
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (en) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 Eryhromycin a derivatives and process of method for the same
DE3860503D1 (en) 1987-09-03 1990-10-04 Pliva Pharm & Chem Works 10-DIHYDRO-10-DEOXO-11-AZAERYTHRONOLID-A COMPOUNDS, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS AND THE PRODUCTION THEREOF.
BE1001869A3 (en) * 1988-10-12 1990-04-03 Franz Legros METHOD OF PACKAGING liposomal AMINOGLUCOSIDIQUES ANTIBIOTICS IN PARTICULAR THE GENTAMYCIN.
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
TW271400B (en) 1992-07-30 1996-03-01 Pfizer
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (en) 1992-11-05 1994-12-23 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
JPH07126172A (en) 1993-11-05 1995-05-16 Genichiro Soma Lps-containing anti-mrsa agent and anti-mrsa agent for animal
FR2718450B1 (en) 1994-04-08 1997-01-10 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
FR2719587B1 (en) 1994-05-03 1996-07-12 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (en) 1995-10-09 1997-12-19 Roussel Uclaf NOVEL DERIVATIVES OF 5-0-DESOSAMINYL 6-O-METHYL ERYTHRONOLIDE A, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE PREPARATION OF BIOLOGICALLY ACTIVE PRODUCTS
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (en) 1995-12-22 1998-01-30 Roussel Uclaf NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
FR2745290B1 (en) 1996-02-28 1998-04-03 Roussel Uclaf NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
PL188173B1 (en) 1996-09-04 2004-12-31 Abbott Lab 6-o-substituted ketolydes of antibacterial activity
JP2002514197A (en) 1996-12-13 2002-05-14 イーライ・リリー・アンド・カンパニー Inhibitor of PSA enzyme activity
ID24529A (en) 1997-06-11 2000-07-20 Pfizer Prod Inc 9-OKSIMA ERITROMICIN DESIGNS
HN1998000086A (en) 1997-06-11 1999-03-08 Pfizer Prod Inc DERIVATIVES OF 9 - DESOFO - 9 AZA - 9A - HOMOERITROMICINA A - C - 4 SUBSTITUTED.
HN1998000074A (en) 1997-06-11 1999-01-08 Pfizer Prod Inc DERIVATIVES FROM MACROLIDES C-4 SUBSTITUTED
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000159A (en) 1997-10-29 1999-02-09 Monsanto Co DERIVATIVES OF 9- AMINO - 3 CETO ERITROMICINA
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
PT1421939E (en) 1998-03-26 2010-07-12 Astellas Pharma Inc Sustained release preparation of a macrolide compound like tacrolimus
FR2777282B1 (en) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc NEW DERIVATIVES OF 2-FLUORO 3-DE ((2,6-DIDEOXY 3-C-METHYL 3-0-METHYL-ALPHA-L-RIBOHEXOPYRANOSYL) OXYL) 6-O-METHYL 3-OXO ERYTHROMYCIN, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE SYNTHESIS OF ACTIVE INGREDIENTS OF MEDICINES
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (en) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc NOVEL DERIVATIVES OF ERYTHROMYCIN, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS
KR100317907B1 (en) 1998-11-24 2001-12-24 김 완 주 Novel Intermediates, process for preparing macrolide antibiotic agent therefrom
FR2786188B1 (en) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
EP1137654A1 (en) 1998-12-10 2001-10-04 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
OA11753A (en) 1999-01-27 2005-07-19 Pfizer Prod Inc Ketolide antibiotics.
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (en) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
AR023264A1 (en) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical ERYTHROMYCIN DERIVATIVES
JP2000351794A (en) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd Erythromycin derivative
DE60030847T2 (en) 1999-04-16 2007-04-19 Kosan Biosciences, Inc., Hayward ANTI-INFECTIOUS MAKROLIDE DERIVATIVES
JP2002542197A (en) 1999-04-16 2002-12-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ketolide antibacterial agent
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (en) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU3337900A (en) 1999-08-09 2001-03-05 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (en) 1999-11-24 2002-05-15 민경윤 Improved method of preparing clarithromycin
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2001261694A (en) 2000-03-06 2001-09-26 Pfizer Prod Inc Ketolide antibiotic
ATE338053T1 (en) 2000-03-15 2006-09-15 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING NON-PHARMACEUTICAL QUALITY CLARYTHROMYCIN
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
FR2821747B1 (en) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques SUSPENSION OF TELITHROMYCIN WITH A MASK TASTE
PT1320355E (en) 2001-05-18 2006-08-31 Chiron Corp SYSTEM FOR ADMINISTRATION OF AN TOBRAMYCIN FORMULATION
FR2826274B1 (en) 2001-06-21 2003-09-26 Aventis Pharma Sa PHARMACEUTICAL FORMULATION FOR MASK TASTE AND METHOD FOR PREPARING THE SAME
AU2002316550A1 (en) 2001-07-03 2003-01-21 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
BR0307898A (en) 2002-02-22 2004-12-07 Pharmacia Corp Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
DK2226316T3 (en) 2002-05-30 2016-04-11 Scripps Research Inst Copper catalyzed ligation of azides and acetylenes
KR20060011784A (en) 2002-06-17 2006-02-03 에피제네시스 파마슈티칼스 아이엔씨 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
NZ537717A (en) 2002-07-08 2006-04-28 Pliva Istrazivacki Inst D New compounds, compositions and methods for treatment of inflammatory diseases and conditions
US20040013737A1 (en) 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (en) 2002-10-29 2004-04-30 Zambon Spa 9A-AZALIDS WITH ANTI-INFLAMMATORY ACTIVITY.
ES2552682T3 (en) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Novel antibacterial agents
WO2004096823A2 (en) 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
EP1618119A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Pyridyl substituted ketolide antibiotics
CA2525455A1 (en) 2003-05-13 2004-11-25 Glaxo Group Limited Novel 14 and 15 membered-ring compounds
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
CA2559281A1 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
ATE439367T1 (en) 2004-05-06 2009-08-15 Glaxosmithkline Zagreb ESTER BONDED MACROLIDES SUITABLE FOR THE TREATMENT OF MICROBIAL INFECTIONS
JP2008508322A (en) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド Ketolide derivatives as antibacterial agents
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
UA85937C2 (en) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Macrolide compounds
US20080113926A1 (en) 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
ATE523519T1 (en) 2005-01-14 2011-09-15 Glaxo Group Ltd MACROLIDE COMPOUNDS WITH BIOTIN AND PHOTO AFFINITY GROUP FOR IDENTIFYING A MACROLIDE TARGET
ATE429921T1 (en) 2005-01-14 2009-05-15 Glaxosmithkline Zagreb 9A-CARBAMOYL AND THIOCARBAMOYLAZALIDE WITH ANTIMALARIA EFFECT
US9597314B2 (en) 2005-03-22 2017-03-21 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20070015719A1 (en) 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
PL1910346T3 (en) 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
WO2007060518A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
DOP2006000268A (en) 2005-12-22 2007-07-31 Pfizer Prod Inc ANTIBACTERIAL AGENTS
FR2897154B1 (en) 2006-02-08 2008-03-07 Airbus France Sas DEVICE FOR BUILDING AND SECURING A LOW ALTITUDE FLIGHT PATH TO BE FOLLOWED BY AN AIRCRAFT.
CN101045063B (en) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 Clarithromycin water soluble preparation for injection use
US8124744B2 (en) 2006-05-01 2012-02-28 Taisho Pharmaceutical Co., Ltd. Macrolide derivatives
US20070281894A1 (en) 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (en) 2006-08-25 2014-04-02 天津和美生物技术有限公司 Antibiotic compound containing aminoglycoside antibiotic
EP2078034A2 (en) 2006-09-18 2009-07-15 The University of Manitoba Synthesis of carbohydrate-templated amino acids and methods of using same
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
ES2363178T3 (en) 2006-12-04 2011-07-26 Astrazeneca Ab ANTIBACTERIAL POLICE POLICYCLY COMPOUNDS.
JP5025249B2 (en) 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 Starting clutch
WO2009053259A1 (en) 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Process for the preparation of macrolide antibacterial agents
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US20100143505A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Indanone inhibitors of acetylcholinesterase
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
RU2016109404A (en) 2009-06-03 2018-11-26 АльгиФарма АС Treatment of akinetobacteria with alginate oligomers and antibiotics
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
WO2011112864A1 (en) * 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
DK2550286T3 (en) 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
WO2012012257A2 (en) 2010-07-19 2012-01-26 Virginia Commonwealth University BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING Aβ OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE
WO2012030513A2 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc Hydrogen bond forming fluoro ketolides for treating diseases
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
CN103619849B (en) 2011-03-01 2016-05-25 沃克哈特有限公司 The preparation method of ketone lactone intermediate
JP6072778B2 (en) 2011-05-23 2017-02-01 シーイーエム—１０２ ファーマシューティカルズ，インコーポレイテッド Compositions containing fusidic acid and packages therefor
PT2748165T (en) 2011-08-27 2016-12-28 Wockhardt Ltd 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
AR091790A1 (en) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc DERIVATIVES OF ISOQUINOLIN-1-ONA AND ITS USES
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
KR20140139083A (en) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. Parenteral formulations for administering macrolide antibiotics
JP6426696B2 (en) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド Methods and formulations for the treatment of respiratory diseases
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN111825733A (en) 2013-04-04 2020-10-27 哈佛大学的校长及成员们 Macrolides and methods of making and using the same
US20170165286A1 (en) 2014-02-14 2017-06-15 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
JP2017523132A (en) 2014-05-27 2017-08-17 ディフアルマ フランチス ソシエタ ア レスポンサビリタ リミタータＤｉｐｈａｒｍａ Ｆｒａｎｃｉｓ Ｓ．Ｒ．Ｌ． Azidoalkylamine salts and their use as intermediates
CN106604729A (en) 2014-08-05 2017-04-26 森普拉制药公司 Powder oral suspension formulations of antibacterial agents
PE20180219A1 (en) 2015-03-06 2018-01-31 Cempra Pharmaceuticals Inc PROCESSES TO PREPARE FLUOROCETOLIDES
TW201811811A (en) 2016-09-02 2018-04-01 森普拉製藥公司 Processes for preparing fluoroketolides

Also Published As

Publication number Publication date
US20150342977A1 (en) 2015-12-03
JP2018030848A (en) 2018-03-01
MX2014011537A (en) 2015-02-10
KR20140139083A (en) 2014-12-04
JP2015512413A (en) 2015-04-27
IL254005B (en) 2019-09-26
IL234769A (en) 2017-08-31
JP6208742B2 (en) 2017-10-04
NZ700182A (en) 2017-02-24
JP6378408B2 (en) 2018-08-22
US20190328759A1 (en) 2019-10-31
AU2013239696A1 (en) 2014-10-09
RU2658050C2 (en) 2018-06-19
CA2868262A1 (en) 2013-10-03
CN104470527A (en) 2015-03-25
AU2013239696C1 (en) 2018-11-29
HK1208622A1 (en) 2016-03-11
SG11201405895UA (en) 2014-10-30
WO2013148891A1 (en) 2013-10-03
RU2014139169A (en) 2016-05-20
CN104470527B (en) 2019-05-28
EP2830632A1 (en) 2015-02-04
HK1205939A1 (en) 2015-12-31
AU2013239696B2 (en) 2017-12-14
IL254005A0 (en) 2017-10-31
US10188674B2 (en) 2019-01-29
EP2830632A4 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
IN2014DN08939A (en)
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
TN2017000067A1 (en) Compounds that inhibit mcl-1 protein
NZ708593A (en) Novel pyrazole derivative
UA96964C2 (en) Antibacterial polycyclic urea compounds
UA114906C2 (en) Heterocyclyl compounds
MX2010009163A (en) Heterocyclic urea derivatives and methods of use thereof-211.
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
WO2012054500A3 (en) Compositions for drug administration
UA118261C2 (en) Chemical entities
MX2014002171A (en) Combination treatments for hepatitis c.
EP4360621A3 (en) Formulations of bendamustine
MX2010013310A (en) Heterocyclic urea derivatives for the treatment of bacterial infections.
CY1120602T1 (en) [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES FOR USE IN THE TREATMENT OF MULTIPLATERIC DISEASES
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022013450A (en) Pharmaceutical formulations.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IN2015DN02109A (en)
MX2015014905A (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
WO2014145713A3 (en) Aminoglycoside antibiotics with reduced ototoxicity
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
WO2014184726A3 (en) Compounds and their use in therapy
UA94177C2 (en) antimicrobial composition